<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl0001">
 <label>Table 1</label>
 <caption>
  <p>Agents Considered for the Treatment of COVID-19 Relevant to HCT, and Common Drugs Used in HCT Relevant to COVID-19 Infection</p>
 </caption>
 <alt-text id="alt0002">Table 1</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th valign="top">Drug Name</th>
    <th valign="top">COVID-19 Studies</th>
    <th valign="top">Use in HCT</th>
    <th valign="top">Special Considerations</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td colspan="4" align="left" valign="top">Agents with the greatest promise</td>
   </tr>
   <tr>
    <td valign="top">Remdesivir</td>
    <td valign="top">Benefit in animal models against the MERS virus and SARS virus; therefore, may have potential activity against COVID-19 [
     <xref rid="bib0031" ref-type="bibr">31</xref>,
     <xref rid="bib0032" ref-type="bibr">32</xref>]. On May 2020, the FDA approved remdesivir for severely ill hospitalized patients 
     <xref rid="bib0033" ref-type="bibr">[33]</xref>. A randomized study showed no statistically significant improvement in the primary endpoint 
     <xref rid="bib0034" ref-type="bibr">[34]</xref>.
    </td>
    <td valign="top">No definite role specifically in HCT.</td>
    <td valign="top">Use only in the context of clinical trials. Can cause hepatotoxicity, thereby caution in patients with liver GVHD</td>
   </tr>
   <tr>
    <td valign="top">Tocilizumab</td>
    <td valign="top">Single-arm trial showing moderate/minimal impact on clinical outcomes 
     <xref rid="bib0035" ref-type="bibr">[35]</xref>. Approved in China for treatment of COVID-19 complications 
     <xref rid="bib0036" ref-type="bibr">[36]</xref>.
    </td>
    <td valign="top">Used for the treatment of acute GVHD.</td>
    <td valign="top">Reactivation of hepatitis B, hepatotoxicity, and serious infections can occur.</td>
   </tr>
   <tr>
    <td valign="top"/>
    <td valign="top">ARDS is usually associated with IL-6 increase thereby providing the rationale for anti-IL6 or anti-IL6 receptor antibody therapy [
     <xref rid="bib0028" ref-type="bibr">28</xref>,
     <xref rid="bib0037" ref-type="bibr">37</xref>].
    </td>
    <td valign="top">Also used for the treatment of cytokine release syndrome after CAR T cell therapy.</td>
    <td valign="top">Consider avoiding in cases of active liver GVHD.</td>
   </tr>
   <tr>
    <td valign="top"/>
    <td valign="top">Tocilizumab also increases the risk of secondary infections 
     <xref rid="bib0038" ref-type="bibr">[38]</xref>.
    </td>
    <td valign="top"/>
    <td valign="top">If supply is an issue, then reserve it for COVID-19 patient clinical trials and use alternate agents for acute GVHD.</td>
   </tr>
   <tr>
    <td valign="top"/>
    <td valign="top"/>
    <td valign="top"/>
    <td valign="top">CAR T cell approved therapy may be affected due to the restricted availability of this drug; thus, consider limiting CAR T cell therapy to those with an urgent need.</td>
   </tr>
   <tr>
    <td valign="top">Convalescent plasma recovered from COVID-19 patients</td>
    <td valign="top">Failure of clinical improvement in 2 case series [
     <xref rid="bib0039" ref-type="bibr">39</xref>,
     <xref rid="bib0040" ref-type="bibr">40</xref>]. Hundreds of trials currently underway. Exact role in COVID-19 trials undefined.
    </td>
    <td valign="top">Not used in GVHD or HCT.</td>
    <td valign="top">Allergic reactions can occur.</td>
   </tr>
   <tr>
    <td valign="top"/>
    <td valign="top"/>
    <td valign="top"/>
    <td valign="top">Given the weak data on efficacy reported so far, it should be used only in clinical trials.</td>
   </tr>
   <tr>
    <td colspan="4" align="left" valign="top">
     <break/>Agents that likely will not work, according to the literature
    </td>
   </tr>
   <tr>
    <td valign="top">Azithromycin</td>
    <td valign="top">Tested in a French trial and found to reinforce the positive effect of hydroxychloroquine on the COVID-19 viral load 
     <xref rid="bib0041" ref-type="bibr">[41]</xref>.
    </td>
    <td valign="top">Used as a treatment for lung GVHD (BOS).</td>
    <td valign="top">Can cause QTc prolongation, torsades de pointes, ventricular tachycardia, and sudden cardiac death, especially when used together with chloroquine.</td>
   </tr>
   <tr>
    <td valign="top"/>
    <td valign="top"/>
    <td valign="top"/>
    <td valign="top">A significant number of patients with GVHD will also be on “azoles” for antifungal prophylaxis, so the risk of QTc prolongation could be further enhanced if used concurrently with full-dose azithromycin, chloroquine, or both.</td>
   </tr>
   <tr>
    <td valign="top">Chloroquine and hydroxychloroquine</td>
    <td valign="top">Best evidence thus far has failed to demonstrate benefit in hard clinical outcomes, but some trial results have been encouraging, with a suggestion of reduced viral load or reduced PCR positivity of COVID-19 
     <xref rid="bib0042" ref-type="bibr">[42]</xref>.
    </td>
    <td valign="top">Used occasionally to treat chronic GVHD.</td>
    <td valign="top">Metabolized by cytochrome P450. Significant QTc prolongation.</td>
   </tr>
   <tr>
    <td valign="top"/>
    <td valign="top">One US retrospective analysis showed no benefit and association with higher mortality in patients receiving hydroxychloroquine 
     <xref rid="bib0043" ref-type="bibr">[43]</xref>. Other studies have shown no benefit and potential harm, such as arrhythmias 
     <xref rid="bib0044" ref-type="bibr">44</xref>, 
     <xref rid="bib0045" ref-type="bibr">45</xref>, 
     <xref rid="bib0046" ref-type="bibr">46</xref>, 
     <xref rid="bib0047" ref-type="bibr">47</xref>.
    </td>
    <td valign="top"/>
    <td valign="top">Concerns about increased toxicity with cyclosporine and imatinib (used in chronic GVHD), such as myopathies.</td>
   </tr>
   <tr>
    <td colspan="4" align="left" valign="top">Agents that possibly may work</td>
   </tr>
   <tr>
    <td colspan="4" align="left" valign="top">Antivirals</td>
   </tr>
   <tr>
    <td valign="top">Lopinavir/ritonavir</td>
    <td valign="top">Recently published trials showed no significant effect on mortality. Very low-level evidence due to risk of bias, such as lack of blinding 
     <xref rid="bib0048" ref-type="bibr">[48]</xref>.
    </td>
    <td valign="top">No definite role specifically in HCT.</td>
    <td valign="top">Severe GI symptoms, QTc prolongation, and multiple drug interactions due to CYP3A inhibition, especially with salmeterol-fluticasone, which, as the FAM protocol, is used frequently used to treat BOS.</td>
   </tr>
   <tr>
    <td valign="top">Favipiravir</td>
    <td valign="top">Preliminary results of a Japanese clinical trial showed that in COVID-19, compared with arbidol, favipiravir did not significantly improve the clinical recovery rate at day 7 
     <xref rid="bib0049" ref-type="bibr">[49]</xref>.
    </td>
    <td valign="top">No definite role specifically in HCT.</td>
    <td valign="top">Elevated serum uric acid has been associated with the use of favipiravir.</td>
   </tr>
   <tr>
    <td valign="top">Herbal therapies: 
     <italic>Nigella sativa</italic>
    </td>
    <td valign="top">Potential demonstrated in molecular docking study 
     <xref rid="bib0050" ref-type="bibr">[50]</xref>.
    </td>
    <td valign="top">No role in HCT but has the propensity to cause prolonged QTc</td>
    <td valign="top">Use should be strictly within the context of a clinical trial.</td>
   </tr>
   <tr>
    <td valign="top"/>
    <td valign="top"/>
    <td valign="top"/>
    <td valign="top">Avoid use in patients with lung GVHD receiving azithromycin.</td>
   </tr>
   <tr>
    <td colspan="4" align="left" valign="top">Cytokine inhibitors</td>
   </tr>
   <tr>
    <td valign="top">Eculizumab</td>
    <td valign="top">Improvement in the COVID-19-associated ARDS/pneumonia in a case series 
     <xref rid="bib0051" ref-type="bibr">[51]</xref>.
    </td>
    <td valign="top">Treatment for HCT-associated microangiopathy (TTP).</td>
    <td valign="top">Given its association with a serious increase in the risk of infection (meningococcus), use only in clinical trials.</td>
   </tr>
   <tr>
    <td valign="top">Siltuximab</td>
    <td valign="top">An improvement in the clinical condition was observed in 33% (7 of 21) of patients, 43% (9 of 21) of patients stabilized, as evidenced by no clinically relevant change in their condition, and 24% (5 of 21) experienced a worsening of their condition 
     <xref rid="bib0043" ref-type="bibr">[43]</xref>.
    </td>
    <td valign="top">Approved by the EMA and FDA for treatment of adults with HHV6-/HIV- multicentric Castleman's disease</td>
    <td valign="top">Use only in the context of clinical trials.</td>
   </tr>
   <tr>
    <td valign="top">Ruxolitinib</td>
    <td valign="top">Possible role in hemophagocytic lymphohistiocytosis due to COVID-19 (trials started)</td>
    <td valign="top">Approved for the treatment of steroid-refractory acute GVHD.</td>
    <td valign="top">Risk of infection and thrombocytopenia with full-dose ruxolitinib. Thrombocytopenia and an ITP-like syndrome have been described in COVID-19 patients; thus, cautious use in clinical trials only is recommended.</td>
   </tr>
   <tr>
    <td valign="top">Ibrutinib</td>
    <td valign="top">Reported as perhaps beneficial for COVID-19 in a retrospective study 
     <xref rid="bib0052" ref-type="bibr">[52]</xref>.
    </td>
    <td valign="top">Approved therapy for chronic GVHD.</td>
    <td valign="top">All patients on the reported study were already on ibrutinib.</td>
   </tr>
   <tr>
    <td colspan="4" align="left" valign="top">Caution against using ibrutinib solely for COVID-19 infection in HCT recipients until trial data available</td>
   </tr>
   <tr>
    <td colspan="4" align="left" valign="top">Immunosuppressives</td>
   </tr>
   <tr>
    <td valign="top">Corticosteroids</td>
    <td valign="top">Dexamethasone has been shown to improve mortality in COVID-19 patients 
     <xref rid="bib0053" ref-type="bibr">[53]</xref>.
    </td>
    <td valign="top">The primary treatment for both acute and chronic GVHD.</td>
    <td valign="top">Judicious use of corticosteroids if needed.</td>
   </tr>
   <tr>
    <td valign="top"/>
    <td valign="top">IDSA recommendation only in cases of MAS or ARDS due to COVID-19 [
     <xref rid="bib0054" ref-type="bibr">54</xref>,
     <xref rid="bib0055" ref-type="bibr">55</xref>].
    </td>
    <td valign="top"/>
    <td valign="top">Risk of osteonecrosis high in HCT recipients.</td>
   </tr>
   <tr>
    <td valign="top">Mesenchymal stromal cells</td>
    <td valign="top">Improved outcome in a single-arm trial of 7 patients 
     <xref rid="bib0056" ref-type="bibr">[56]</xref>.
    </td>
    <td valign="top">Approved treatment for acute GVHD in Canada, New Zealand, and Japan</td>
    <td valign="top">Can be used in the context of clinical trials both autologous and allogeneic HCT recipients.</td>
   </tr>
   <tr>
    <td valign="top"/>
    <td valign="top">Multiple trials going on in ARDS due to COVID-19</td>
    <td valign="top"/>
    <td valign="top"/>
   </tr>
   <tr>
    <td colspan="4" align="left" valign="top">Interactions with other drugs</td>
   </tr>
   <tr>
    <td valign="top">Voriconazole and posaconazole</td>
    <td valign="top">No known role in COVID-19</td>
    <td valign="top">Commonly used in GVHD.</td>
    <td valign="top">Azithromycin interaction with the CYP3A4 inducers.</td>
   </tr>
   <tr>
    <td valign="top">CAR T cells (cryopreserved vs. fresh products)</td>
    <td valign="top">No role in COVID-19</td>
    <td valign="top">Approved for post-transplantation relapse of ALL and NHL.</td>
    <td valign="top">Post-CAR T cell infusion, any drug treatment should strictly be in the context of clinical trials.</td>
   </tr>
   <tr>
    <td valign="top"/>
    <td valign="top"/>
    <td valign="top"/>
    <td valign="top">CAR T cell therapy may be affected owing to the restricted availability of tocilizumab; therefore, consider CAR T cell therapy only for those with an urgent need.</td>
   </tr>
   <tr>
    <td valign="top"/>
    <td valign="top"/>
    <td valign="top"/>
    <td valign="top">General guidance from the CAR T cell consortium should be considered 
     <xref rid="bib0009" ref-type="bibr">[9]</xref>.
    </td>
   </tr>
   <tr>
    <td valign="top">ACE inhibitors</td>
    <td valign="top">Hypothetically could increase the likelihood of acquiring SARS-CoV-2 by increasing ACE2 expression (virus-binding site) [
     <xref rid="bib0057" ref-type="bibr">57</xref>,
     <xref rid="bib0058" ref-type="bibr">58</xref>].
    </td>
    <td valign="top">No known role for treatment of any aspect of HCT.</td>
    <td valign="top">Until data are available, do not stop ACE inhibitors in HCT recipients who are already on treatment.</td>
   </tr>
   <tr>
    <td valign="top">Arbidol</td>
    <td valign="top">A Chinese randomized controlled open-labeled trial demonstrated arbidol monotherapy had little benefit for mild/moderate COVID-19 infection 
     <xref rid="bib0059" ref-type="bibr">[59]</xref>.
    </td>
    <td valign="top">No definite role specifically in HCT.</td>
    <td valign="top">Adverse events include diarrhea and nausea.</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>BOS indicates bronchiolitis obliterans syndrome; MERS, Middle East respiratory syndrome; ACE: angiotensin-converting enzyme; MAS, macrophage activation syndrome; TTP, thrombotic thrombocytopenic purpura; EMA, European Medicines Agency; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
